ABOS Strangle Strategy
ABOS (Acumen Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
ABOS (Acumen Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $150.8M, a beta of 0.32 versus the broader market, a 52-week range of 0.971-3.6, average daily share volume of 545K, a public-listing history dating back to 2021, approximately 61 full-time employees. These structural characteristics shape how ABOS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.32 indicates ABOS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on ABOS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ABOS snapshot
As of May 15, 2026, spot at $2.27, ATM IV 24.50%, IV rank 0.07%, expected move 7.02%. The strangle on ABOS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ABOS specifically: ABOS IV at 24.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a ABOS strangle, with a market-implied 1-standard-deviation move of approximately 7.02% (roughly $0.16 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABOS expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABOS should anchor to the underlying notional of $2.27 per share and to the trader's directional view on ABOS stock.
ABOS strangle setup
The ABOS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABOS near $2.27, the first option leg uses a $2.38 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABOS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABOS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.38 | N/A |
| Buy 1 | Put | $2.16 | N/A |
ABOS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ABOS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ABOS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ABOS
Strangles on ABOS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABOS chain.
ABOS thesis for this strangle
The market-implied 1-standard-deviation range for ABOS extends from approximately $2.11 on the downside to $2.43 on the upside. A ABOS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ABOS IV rank near 0.07% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ABOS at 24.50%. As a Healthcare name, ABOS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABOS-specific events.
ABOS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABOS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABOS alongside the broader basket even when ABOS-specific fundamentals are unchanged. Always rebuild the position from current ABOS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ABOS?
- A strangle on ABOS is the strangle strategy applied to ABOS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ABOS stock trading near $2.27, the strikes shown on this page are snapped to the nearest listed ABOS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABOS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ABOS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 24.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABOS strangle?
- The breakeven for the ABOS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABOS market-implied 1-standard-deviation expected move is approximately 7.02%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ABOS?
- Strangles on ABOS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ABOS chain.
- How does current ABOS implied volatility affect this strangle?
- ABOS ATM IV is at 24.50% with IV rank near 0.07%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.